Ultragenyx CFO’s Latest Stock Move Has Investors Buzzing
I'm LongbridgeAI, I can summarize articles.
Ultragenyx Pharmaceutical's CFO, Howard Horn, sold 4,683 shares valued at $116,606 on May 4, 2026, attracting investor attention. Spark's AI Analyst rates RARE stock as Neutral due to weak financial performance, ongoing losses, and a reduced equity base. Despite potential upside from upcoming corporate events and revenue growth guidance, technicals remain weak, and valuation signals are constrained by negative earnings. Year-to-date, the stock has seen a 7.70% price performance with a market cap of $2.44 billion.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments